Cargando…

Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach

PURPOSE: The purpose of this study was to provide evidence-based recommendations of intermittent androgen deprivation therapy (IADT) compared with continuous androgen deprivation therapy (CADT) for men with prostate cancer (PCA). METHODS: We conducted a comprehensive search in MEDLINE, EMBASE, The C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonfill, Xavier, Arevalo-Rodriguez, Ingrid, Martínez García, Laura, Quintana, Maria Jesús, Buitrago-Garcia, Diana, Lobos Urbina, Diego, Cordero, José Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080876/ https://www.ncbi.nlm.nih.gov/pubmed/30122985 http://dx.doi.org/10.2147/CMAR.S164856

Ejemplares similares

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer
por: MURESANU, HORIA
Publicado: (2016)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
por: Abrahamsson, Per-Anders
Publicado: (2017)

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020)

Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer
por: Golabek, Tomasz, et al.
Publicado: (2016)

AB37. The combination of I brachytherapy with intermittent androgen deprivation in treating locally advanced prostate cancer
por: Huang, Yi
Publicado: (2014)

Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain
por: Bonfill-Cosp, Xavier, et al.
Publicado: (2022)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy
por: Maru, Shintaro, et al.
Publicado: (2018)

Quality assessment of controlled clinical trials published in Orthopaedics and Traumatology journals in Spanish: An observational study through handsearching and evidence mapping
por: Arevalo-Rodriguez, Ingrid, et al.
Publicado: (2018)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years
por: Shida, Yohei, et al.
Publicado: (2017)

Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy
por: Alsinnawi, Mazen, et al.
Publicado: (2019)

Effects of androgen deprivation therapy duration and Gleason grade on survival outcomes of high risk prostate cancer
por: Kim, Do Kyung, et al.
Publicado: (2019)

Androgen deprivation therapy and Gleason grade: unravelling implications on survival
por: Scott, Michael, et al.
Publicado: (2019)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation
por: Aversa, Antonio, et al.
Publicado: (2012)

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2014)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research
por: Parikh, Rahul A, et al.
Publicado: (2014)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2011)

Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells
por: Sánchez, Belén G., et al.
Publicado: (2020)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Leukodepleted Packed Red Blood Cells Transfusion in Patients Undergoing Major Cardiovascular Surgical Procedure: Systematic Review and Meta-Analysis
por: Simancas-Racines, Daniel, et al.
Publicado: (2019)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Transcription Factors Involved in Prostate Gland Adaptation to Androgen Deprivation
por: Rosa-Ribeiro, Rafaela, et al.
Publicado: (2014)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kqc8avimmupsqa588nq2kndfmf